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1. Introduction 
Liver fibrogenesis is the consequence of all hepatic lesions, regardless of etiology. 
Progressive scars, which are the response to constant liver injuries lead to cirrhosis, 
disorganize  the normal liver architecture through fibrosis bands, parenchyma nodules and 
blood vessel distortions. For this reason, liver fibrosis is a central parameter which expresses 
the severity of liver diseases, regardless of etiology; it is a key element which predicts the 
evolution of liver diseases towards cirrhosis.  
Irrespective of the cirrhosis etiology, the clinical evolution is similar, towards major 
complications such as: portal hypertension and hepatocellular insufficiency. Due to these 
complications, cirrhosis is the seventh death cause within general mortality. Cirrhosis also 
encourages the development of hepatocellular carcinoma, an aggressive neoplasm which 
causes death in a few months in the absence of early diagnosis. That is why liver fibrosis is a 
major criterion in initiating the etiologic treatment of chronic liver diseases.  
A long time ago, liver fibrosis was deemed irreversible. This axioma has been discarded for 
quite some time; at present, fibrosis is considered to be a bidirectional dynamic 
phenomenon: fibrogenesis and fibrinolysis. Thus, it is possible to reshape the scar healing 
tissue. Due to this dynamic process, it is necessary to quantify fibrosis in order to set the 
therapeutic decision and especially to monitor the efficiency of anti fibrotic treatments. 
There are several methods to diagnose liver fibrosis: liver biopsy, serum biomarkers, breath 
tests and hepatic elastography. Liver biopsy is currently essential in diagnosis of 
inflammatory and metabolic liver diseases. It provides particularly invaluable informations 
for disease diagnosis and patient monitoring.  
The role of liver biopsy is still a controversial issue being an invasive method with well-
known risks and complications. Although liver biopsy is considered the golden standard for 
chronic liver diseases, it is worth mentioning that the histological tested fragment is 
however a small part of the liver, and the scar lesions, which are secondary to chronic 
inflammatory processes are unevenly distributed in the liver mass. Thus, liver biopsy  is a 
method neither ideal nor sufficient to diagnose and determine the stage of liver fibrosis. In 
this context, a noninvasive method to assess liver fibrosis is more than welcome. 
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Noninvasive tests can be classified in several ways based on the modality of the test (serum 
blood tests or imaging) or the constituents of the tests (direct markers versus indirect 
markers of fibrosis). With the evolution of noninvasive tests, the performance can improve 
particularly with the use of combination or serial noninvasive tests.  
In this  chapter the role of liver biopsy and non-invasive tests to assess  liver fibrosis and to 
manage the treatment of patients with chronic liver disease is discussed. 
2. Liver biopsy 
Liver biopsy was first described by Paul Ehrlich, 130 years ago, as a diagnostic tool of the 
chronic liver disease. It can be performed using blind percutaneous technique, computer 
tomography or ultrasound-guided, transjugular, open surgical, laparoscopic and even 
endoscopic approaches.  
Microscopic  examination of liver tissue often provides the definitive diagnosis and leads to 
effective management of the liver disorders. Because fibrosis is tissue damage, biopsy is by 
definition the only direct tool to assesses liver fibrosis. 
2.1 When is liver biopsy useful? 
The major indication for performing a liver biopsy is to clarify the nature of liver disease. In 
some instances, liver biopsy is performed to establish the effect of the treatment in known 
liver disease. In chronic viral hepatitis, the knowledge of liver fibrosis stage is important for 
prognosis and for decision  about the antiviral treatment.  Significant fibrosis (F≥ 2) in these 
patients is an indication for antiviral treatment.  
In patients with alcoholic liver diseases, the clinical features and the values of serum 
aminotransferases are poorly correlated with the liver diseases stage and the long-term 
prognosis strictly depends on the severity of histological lesions.  In alcoholic liver disease, 
the biopsy can reveal fatty liver infiltration, large shape of hepatocytes, the presence of 
Mallory bodies, or polimorfonuclear infiltrates in portal spaces, and also histological 
features specific to cirrhosis. On the other side, fatty liver infiltration occurs in various 
etiologic situations: obesity, diabetes, consumption of alcoholic beverages, chronic HCV 
infection  and the liver biopsy may provide  distinct etiologic information. 
In patients with chronic hepatitis C there is a low correlation between symptoms, serum 
aminotransferases and histological modifications; thus, serum aminotransferases may have 
normal values, but liver histology is suggestive for severe fibrosis or cirrhosis. Liver biopsy 
ensures a certain diagnosis in more than 90% of the patients with unexplainable increase of 
serum aminotransferases. In the same time, it is useful in evaluating infectious complications, 
drug toxicity or the reoccurrence of the primary disease in the transplanted liver. 
In patients who present space replacing liver formations, the indication of liver biopsy is still 
debatable. It is useful to establish  the origin of metastasis when the primary tumor is not 
known, to confirm the metastases in case of diagnosed cancers before and after surgical 
resection. It is also able to certify the benign nature of liver formations.  
In patients with nonresected hepatocellular carcinoma, echographic guidance allows  
specific therapeutically approach like: alcoholization, radiofrequency, chemoembolization. 
In conclusion, liver biopsy is recommended in diagnosis of: 
Infiltrative liver diseasestuberculosis, sarcoidosis, lymphoma, amyloidosis; 
Hereditary disorders: Wilson disease (determining the amount of intrahepatocyte copper 
deposits), hemochromatosis (determining the amount and quality of intrahepatocyte iron 
deposits),  alpha-1 antitrypsin deficiency; 
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Liver cholestasis primary billiary cirrhosis, primary sclerosing cholangitis;. 
Diagnostic uncertainty (abnormal liver tests with no clear etiology: the increase of serum 
aminotransferases, bilirubin, alkaline phosphatase or glutamiltranspeptidase. 
Coexisting disorders: Human immunodeficiency virus [HIV] and hepatitis C virus 
infection, alcoholic liver disease and hepatitis C 
Overlap  syndrome: Primary biliary cirrhosis with autoimmune hepatitis. 
Fatty liver: liver biopsy can distinguish between benign steatosis and progressive 
steatohepatitis; 
Space replacing processes discovered by chance during a routine imagistic check up.  
Periodic needle biopsy is also valuable in the management of a few diseases. 
In autoimmune hepatitis, monitoring the plasma cell score on liver biopsy may help predict 
relapse; 
Liver transplantation: possible complications occurring  after the liver transplant rejection 
or the disease recurrence (Carey & Carey, 2010). 
2.2 The liver biopsy interpretation 
Histologic assessment of a liver biopsy specimen remains the “gold standard” for 
quantifying fibrosis that is essential to guide management and predict prognosis in patients 
with chronic liver injury . 
There is a wide range of methods used to interpret a liver biopsy. For morphological 
analysis of liver liver biopsy is necessary to use either ordinary staining (hematoxilin-eozin), 
or special ones: Masson’s trichrome stain (for fibrosis), Pass stain (for glycogen), Pearls stain 
(for intrahepatocyte iron deposits) and rhodamin (for hepatocyte copper). 
Immunohistochemical  and in situ mRNA hybridization methods to identify specific matrix 
components can be employed for experimental aim and have some utility in assessing 
fibrosis progression. 
The most important role of liver biopsy is the assessment of necroinflammation (grade) 
and fibrosis (stage). The morphological features of chronic viral hepatitis are portal 
fibrosis, portal and periportal mononuclear inflammation and necroinflammatory changes 
within the parenchyma with a an irregular distribution between one lobule and another. 
There is also regenerative activity in an irregular distribution. The degree of necrosis 
depends on the disease activity –more severe during exacerbations and lesser in quiescent 
stages. Fibrosis progresses to cirrhosis and the periseptal inflammatory activity continues 
with cirrhosis . 
A number of numerical scoring systems have been used to evaluate the amount of 
inflammation and degree of fibrosis in liver biopsy specimens from patients with chronic 
liver disease. Histological scores such as Metavir, Knodell, Ishak and Desmet/ Scheuer 
systems were created to standardize the interpretation of liver biopsies. The Knodell system 
was the first staging system, having a total of 18 for necroinflammation and a total of 4 for 
fibrosis (0-4). However, this system is noncontiguous and no longer used. Instead, the Ishak 
system had more details for necroinflammation (0-18) and expanded scores for fibrosis(0-6). 
This may be  helpful  in clinical studies when fine gradations of fibrosis pattern are required 
to demonstrate change, but this system is not commonly used in clinical practice. These 
scores are semi- quantitative scales for evaluation of a complex pathobiological process: 
fibrosis, necroinflammation and finally nodule formation.  The Metavir system is simpler  
with a combination score for inflammation including periportal and lobular activity (A0-A3) 
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and a fibrosis score on a scale of F0-F4. Metavir is the most used system in clinical practice 
today. The accuracy of grading and staging is dependent on the adequacy of the specimen 
and the experience of the pathologist. 
Bedossa considers that the advantages of using the scores for liver biopsy interpretation 
consist in :an increase of reproducibility between pathologists, a standardization of biopsies 
reports, an homogeneity between liver centers, and a better comparison of consecutive 
biopsies for monitoring disease follow-up . The scores also serve as reference for choosing 
and validation of non invasive methods for liver fibrosis assessment. 
 
Appearance 
Ishak stage: 
Categorical description 
ISHAK METAVIR 
 
No fibrosis (Normal) 0 F0 
 
Fibrosis expansion of some portal areas 
± short fibrous septa 
1 F1 
 
Fibrosis expansion of most portal areas 
± short fibrous septa 
2 
F2 
 
Fibrosis expansion of most portal areas 
with occasional portal to portal(P-P) 
bridging 
3 
 
Fibrosis expansion of portal areas with 
marked portal to portal(P-P) bridging 
as well as portal to central( P-C) 
4 
F3 
 
Marked bridging (P-P and/or P-C) 
with occasional nodules (incomplete 
cirrhosis) 
5 
 
Cirrhosis, probable or definite 6 F4 
Table 1. Scoring systems in liver fibrosis.( Standish RA et al.,2006) 
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Fig. 1. Fibrosis stage 1 
 
 
Fig. 2. Fibrosis stage 2 
 
 
Fig. 3. Fibrosis stage 3. 
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Fig. 4. Fibrosis stage 4 
2.3 Complications of liver biopsy  
Liver biopsy is a safe procedure if it is carried out by experienced gastroenterologists. 
Froehlich et al noticed a lower rate of complications in the case of doctors who performed 
over 50 biopsies in a year. Although the liver is a highly irrigated organ,  complications 
after the biopsy are rarely. Thus, it was noted that over 60% of the complications occur 
within two hours and over 90% within the first 24 hours after the procedure. Within out 
patients who present complications, 1-3% require hospitalization, often after Tru-cut type 
needle use. 
Complications may be minor (pain or vagal reactions, blood hypotension) or major. 
Significant complications, defined as those resulting in hospital admission or prolonged 
hospitalisation, occur in 1-5% of patients. The mortality rate is reported between 1:1000 
and 1:10000. The complications of liver biopsy and their frequency are indicated in table 
no. 2 
2.4 Limits of liver biopsy  
The hepatic function is compromised to a minimum until the development of cirrhosis. The 
presence of clinical manifestations such as ascites and encephalopathy are clear evidences of 
the advanced disease.  
So far, only liver biopsy has been able to determine the severity of pre-cirrhotic stages. 
However, the role of liver biopsy as a golden standard in diagnosing liver diseases seems 
to be controversial due to the development of modern imagistic techniques: 
ultrasonography, computer tomography, nuclear magnetic resonance and the appearance of 
noninvasive serum markers.  
Liver biopsy may be the golden standard in assessing liver fibrosis, but it is not 24 karat 
gold. We have to mention that the biopsy needle takes a small fragment from the liver. It is 
important to take into account that a biopsy is merely a sample of the entire liver and the 
scarring in chronic liver disease is typically irregularly distributed in the liver. For this 
reason, the perfect liver biopsy should remove a fragment into a known area  of the disease 
or multiple  fragmentes  in many areas of a diseased liver.  
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Complications of liver biopsy  
Pain at the right hypochondrium, shoulder  0.056-83% 
Arterial hypotension   
Hemorrhagic complications  
sub capsular hematoma: 0.05% 
intrahepatic hematoma: 0.05% 
intraperitoneal bleeding: 0.03% 
hemobilia: 0.05% 
Bacteriemia 0.08% 
Death 0.001-0.0001% 
Bile peritonitis  0.03-0.22% 
Pneumothorax, hemothorax 0.08-0.28% 
Subcutaneous emphysema   0.014% 
Subphrenic abscess   
Anaphylactic shock (hydatid cyst)  
Break of the biopsy needle  0.02% 
Biopsy of other organs  
lungs-0.001% 
bile -0.003% 
colon-0.003% 
kidneys-0.09% 
Table 2. The complications of liver biopsy 
The liver biopsy removes only about 1/50 000th of the liver and can miss the diagnosis of 
cirrhosis in 20% to 30% of patients. That is why, many investigators recommend a biopsy 
length at least 15 mm, containing sixt or eight portal tracts, to improve the diagnostic 
accuracy. Both the size of the biopsy and the number of biopsies taken have a major effect 
on diagnosis accuracy. Although widely used, liver biopsy can be a source of errors given 
by the small size of the samples or the inappropriate sizes of the needle.The length of the 
fragment is proportional to the length of the needle used (18 gauge)  and the size of the liver 
fragment is essential in assessing the hepatic architecture. There are several studies which 
revealed a decrease of diagnosis accuracy in biopsies smaller than 2 cm.  In a study which 
comprised 10.000 virtual biopsies, Bedossa and collaborators showed that the staging of 
liver fibrosis is accurate in 65% of the cases when the analyzed biopsy fragment was at least 
15 mm long, in 75% of the cases when the fragment was at least 25 mm length and that the 
best length should be 40 mm. The same study, in which laparoscopic biopsies were collected 
from both lobes of patients with chronic hepatitis C, estimated that biopsy specimens with a 
minimum 4 cm or greather in length would reliably avoid sampling error. However, in 
many specialized hepatology centers, the biopsy fragment does not meet the best criteria for 
an accurate histological analyse. Surgical wedge biopsy provides adequate tissue volume to 
overcome this problem. 
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Another limitation of the liver biopsy is that is very sensitive to analysis errors. Several 
studies have investigated the interobserver and intraobserver variability in the 
histological diagnosis of liver diseases. To minimize the analysis errors and to standardize 
the histological evaluation, staging scores for fibrosis, such as the METAVIR, Ishak and 
Scheuer systems, were created. Nevertheless, liver biopsy is associated with error in 
fibrosis staging in up to 20% of patients and a misdiagnosis of cirrhosis in up to 15 % of 
patients. In example of the resulting sampling errors that can occur, were considered the 
two most common chronic liver diseases: hepatitis C and fatty liver disease. Regev et al 
(2002) performed laparoscopically  guided biopsy of the right and left hepatic lobes in a 
serie of 124 patients with chronic hepatitis C. The two fragments of the same patient were 
interpreted by the same anatomopathologist who was not awared about the identity of 
the biopsy fragment.  Differences of more than one Metavir stage of fibrosis was present 
in 33,1% of cases and more than 2 stages in 2.4%. In 14.5%, cirrhosis was diagnosed in one 
lobe but not the other. As regards liver diseases of other etiologies than the viral one, 
differences  were even bigger. In a study on patients with nonalcoholic fatty liver disease, 
Ratziu et al found that differences of more than one stage Metavir was present in 
approximately 40% of paired liver biopsy; in the patients with primary sclerosing 
cholangitis or primary biliary cirrhosis, ≥1 fibrosis stage discordances occurred in up to 
60% of paired liver biopsy. 
Clearly, needle liver biopsy is far from an ideal test. For these reasons it is necessary to 
develop some semi-automated systems to assess additional histological and 
immunohistochemical features.   
Another limit of the liver biosy is related to  slow rate of fibrosis progression; from normal 
liver to cirrhosis it takes more than 20 years. Follow-up biopsy is too insensitive to detect 
changes in fibrosis progression or regression within weeks to months and even years.  
From another point of view, liver biopsy is an invasive procedure with certain unavoidable 
risks and complications. For both, the physician and the patient, the decision to proceed 
with liver biopsy is not a trivial one. There is an urgent need for a noninvasive diagnostic 
procedure for liver fibrosis because this is currently the main limitation of antifibrotic drug 
testing in clinical trials. 
3. Noninvasive methods for the evaluation of liver fibrosis  
Liver biopsy has been used in more than a century for the staging and diagnosis of acute or 
chronic liver diseases. In order to monitor patients with chronic liver diseases, liver biopsy 
has been increasingly less used because of the sampling and interpretation errors, the 
patient’s high emotional cost and especially because it captures only one moment in a 
diffuse and evolutive hepatic process. In this context, the identification of a noninvasive 
method for the evaluation of liver fibrosis is a challenging  option.  
Noninvasive testes are an attractive alternative to liver biopsy for staging and monitoring of 
chronic liver diseases. A noninvasive method which provides the same information as liver 
biopsy is also desirable in cases when the latter is not possible.  
The purpose of any noninvasive technique is to replace liver biopsy. These methods have 
the advantage of representing the liver in its entirely unlike puncture which analyzes only a 
limited fragment of liver. They also provide information related to the hepatic function: 
secretion, bile excretion or endothelial uptake.  
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Considering the slowly evolution of chronic liver diseases, the information provided 
through liver puncture is not enough to monitor the disease at short time intervals  ue to the 
minimal histological changes. Noninvasive tests have to be sensitive enough to detect the 
minor changes of the dynamic fibrosis process.  
Another indication of noninvasive tests is that they evaluate the efficiency of antifibrotic 
treatments, which cannot be performed through repeated hepatic punctures. It is important 
to have safe and efficient methods to objectify liver fibrosis from several perspectives. In the 
first place, patients with liver fibrosis are part of a high risk group as regards liver diseases 
mortality. In the second place, the prognosis of chronic liver diseases depends on the 
severity and related risk factors. In the third place, when the etiologic factor can be removed, 
it is important to introduce the antifibrotic therapy as soon as possible to reverse the hepatic 
lesions.  
The criteria used in evaluating the severity of liver diseases through other procedures than 
liver biopsy are not specified yet. That is why, for now, potential noninvasive methods must 
be relatively well correlated with the biopsy. The errors of this histological method prevent 
the perfect correlation between the biopsy and noninvasive tests in the diagnosis and 
staging of liver fibrosis. The best correlation occurs in biopsies > de 2.5 cm, the correlation 
index (r) being 0.85. For the interpretation of noninvasive tests, it is important to consider 
the fact that liver biopsy may fail in 20% of the cases, especially for intermediary forms of 
liver fibrosis. This is the reason why many experts believe that the noninvasive methods 
whose ROC (Receiver Operator Characteristic) curve is 0.85-0.90 are as effective as the 
histological exam in the accurate staging of liver fibrosis.  
The two major categories of noninvasive tests include: serum fibrosis markers and hepatic 
elasticity imaging (elastography). 
The results of noninvasive tests will be interpreted in the clinical context; in case of 
discrepancies, liver biopsy is recommended. 
3.1 Serum fibrosis markers 
The physiopathology‘s knowledge of liver fibrosis has determined a high number of 
biomarkers used to diagnose it. Depending on the elements they represent, there are two 
marker categories: direct (representing components of extracellular matrix) or indirect 
(reflecting hepatic inflammation and function).  
In order to be sensitive and specific, therefore ideal for the diagnosis of liver fibrosis, Afdhal 
N.H (2007) considers that biomarkers have to meet the following requirements: 
 they should be specific hepatic tests; 
 the results should not be influenced by the alteration of the hepatic, renal or 
reticuloendothelial function; 
 they should reflect fibrosis regardless of etiology;  
 they should be reproducible and  easy to perform; 
 they should be sensitive enough to differentiate among various fibrosis stages; 
 the risks for patients should be minimum; 
 the cost should be low. 
Due to the high number of molecules involved in liver fibrosis  efforts were made to compile 
the serum markers within panels for clinical use. More indicators and sophisticated scores 
utilizing direct and indirect markers have been developed to enhance the detecting and 
noninvasive staging of liver fibrosis. The most widely known of these are listed in table no.3. 
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Panel Liver Disease Se Sp PPV NPV 
AST/ALT 
ratio 
AST/ALT 53% 100% 100% 81% 
Forns test Platelets, GGT, Cholesterol 94% 51% 40% 96% 
APRI Index AST, Platelets 41% 95% 88% 64% 
PGA Index Platelets, GGT, apo A 91% 81% 85% 89% 
FibroTest 
GGT, haptoglobin, bilirubin, apoA,  
alpha2-macroglobulin 
87% 59% 63% 85% 
Fibrospect 
Hyaluronic acid, TIMP-1, alpha2-
macroglobulin 
83% 66% 72% 78% 
FPI AST, Cholesterol, HOMA-IR 85% 48% 70% 69% 
ELF ECM proteins and proteinases 90% 41% 35% 92% 
Abbreviations: Se,  sensitivity, Sp, specificity, PPV, positive predictive value, NPV, negative predictive 
value, AST, aspartate aminotransferase, ALT, alanine aminotransferase, GGT, Gamma glutamyl 
transferase, apoA, apolipoprotein A1, TIMP-1, tissue inhibitors of metalloproteinase 1, HOMA-IR, 
homeostasis model assessment of insulin resistance, EMC, extracellular matrix molecules 
Table 3. Diagnostic performances of serum markers panels for hepatic fibrosis compared to 
the referenced standard of liver biopsy (Adapted from Rockey DC& Bissel DM, 2006).   
The serum markers of fibrosis are an attractive, noninvasive and affordable alternative, 
replacing at least part of the liver biopsies used in clinical practice. Crockett et al (2006) 
made a comparison between liver biopsy and serum markers, considering the advantages 
and disadvantages of the two methods used alternatively to diagnose and stage liver 
fibrosis. 
 
Factor Liver biopsy Serum markers 
Cost 2200$ Laboratory cost 
Risks Significant Minimal 
Contraindications 
Multiple: bleeding diathesis, morbid 
obesity, ascites, extrahepatic biliary 
obstruction 
Conditions with high rate of 
false positivity 
Accuracy 80% 60-80% 
System 
requirements 
Operator, pathology laboratory, 
pathologist 
Clinical laboratory, phlebo-
tomy, materials. 
Specimen 
adequacy 
Length of liver fragment at least 15 
mm with  6-8 portal tracts 
Blood sample 
False positives Interobserver variability 
Sepsis, nonhepatic infla-
mmation, hemolysis, trom-
bocitopenia 
False negatives Sampling variability Varies per test 
Time for results 24-72 hours minimum 1-2 hours minimum 
Table 4. Comparison of liver biopsy and serum markers of fibrosis 
The ability of serum tests of fibrosis are similar, with area under the receiver operating 
characteristic curve 0.8-0.85. Compared to biopsy, current serum biomarkers represent the 
whole liver, permit only crude staging sparing about 30-40% patients for biopsy and reflect 
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also liver function (secretion, endotelial uptake).Although their accuracy value are 
improving they cannot supplant direct analysis of the liver. They have some limitatios:  
 They reflect the rate of matrix turnover and tend to be more elevated when there is high 
inflammatory activity; 
 None of the molecules is liver specific, so concurrent sites of inflammation may 
contribute to serum level; 
 Serum levels are influenced by clearance rates; 
The clinical usefulness of serological tests is to set quickly whether fibrosis is mild or severe, 
being less efficient in intermediary fibrosis stages. Most serum markers are more efficient in 
identifying fibrosis that in infirming it. That is why, when fibrosis is severe, regardless of the 
invasive or noninvasive diagnosis method, patients without signs of portal hypertension 
should  start etiologic treatment.  
So far, there is no ideal noninvasive test. Serum markers are based on probability 
calculations and thus they are less specific. Their diagnosis performances increase through 
the combined use of several serum markers tests.  
Using the algorithms based on the sequential combination of serum markers, diagnosis 
accuracy in detecting significant fibrosis can increase to 93-95%, and the liver biopsies could 
be avoided in 50% of the patients with chronic liver diseases. As clinical experience 
accumulates we shall expect that serum markers will begin to replace many of the liver 
biopsies used today for prognostic and treatment purpose.  
Are serum markers ready for the first line fibrosis diagnosis? Overall, the serum assay 
approach remains promising, in part because these tests may represent an “integrated 
readout of liver activity rather than a minute sampling of the type obtained by 
conventional liver biopsy. Initially established as a niche especially in patients who have a 
high risk of complications from liver biopsy, by continued refinement, biomarkers are 
very close to become first line method  for the diagnosis and monitoring of liver fibrosis. 
(Schiff, 2007). 
3.2 Elastography imaging 
Elastography is a much simpler method used to stage liver fibrosis than the X ray methods 
which are commonly used. This technique is quick and noninvasive. It helps to determine 
the stiffness of the hepatic tissue. It is well-known that the stiffness of the hepatic tissue is 
closely related to the stage of liver fibrosis. Touching the firm edge of the liver is a clinical 
parameter used for many years to diagnose cirrhosis. 
3.2.1 Transient Elastography (TE) 
Fibro scan is a device which measures hepatic stiffness through transient elastography. It 
determines the elasticity of a hepatic volume equal to a cylinder with the diameter of 1 cm 
and the length of 4 cm, being thus 100 times larger than the standard biopsy fragment and, 
as such, more representative for the entire hepatic parenchyma.  
Fibro scan uses an ultrasound transducer fixed on the axes of a vibrator which induces a low 
frequency vibration (50 MHz). The vibration transmitted to the hepatic tissue produces an 
elastic wave which propagates inside the liver. The propagation of this wave is followed by 
an ultrasound impulse and the measurement of its speed determines, through direct 
correlation, the tissue stiffness. The more rigid the liver, the higher the propagation speed. 
The results are expressed as kilopascal. Since a larger area of hepatic tissue is studied, 
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diagnosis errors related to the sample size which occur in standard liver biopsy are 
eliminated, even in disorders with focal liver fibrosis. 
This technology has many of the features of a noninvasive  ideal method in evaluating liver 
fibrosis, with a series of advantages: it is quick, reproducible, painless and safe.  
Transient elastography is a relative new method. The first clinical data related to this 
technology were published in 2002. Numerous studies on patients with chronic hepatitis C 
demonstrated that elastography is a safe method for detecting severe fibrosis (Casterra, 
2010). Although it is limited in differentiate the intermediary fibrosis stages, its major 
advantage is that it accurately detects persons with significant fibrosis. 
Usually, 10 measurements are carried out for each patient, the total exam duration being 5-
10 minutes. The success rate is automatically calculated by the machine as a ratio between 
the number of successful measurements and the total number of measurements. The 
recommendations of the manufacturers of this technology are that transient elastography 
can only be validated if there are 10 measurements with a success rate of at least 60%. 
However, recent studies have suggested that 3 validated measurements have the same value 
as 10 measurements for cirrhosis diagnosis; the minimum number of measurements for 
significant fibrosis has still to be set. It is considered that 10 validated measurements and a 
success rate of at least 60% can be obtained in 90% of exams.  
Transient elastography is easy to interpret; the coefficient of concordance for the same 
examiner is 96-98% (the correlation coefficient in the same class) and between examiners, the 
coefficient of concordance is of 89-98%. Measurements validation depends on the IQR 
(interquartile range),  <30%) and the success rate of measurements,  >60%.  
The largest study of hepatic elastography  evaluated 327 patients with chronic infection C 
(Ziol et al, 2005) . For each patient, fibrosis was staged by means of 2 methods: Fibro scan 
and liver biopsy. Metavir scoring system for histological staging of liver fibrosis  served as 
reference. The conclusion was that elastography is a reliable tool to detect significant fibrosis 
or cirrhosis. Table no. 5 indicates the diagnosis performance of Fibro scan in detecting 
significant fibrosis, as well as the authors who reported these results. 
 
Study 
Liver 
disease 
No 
patients 
Prevalence of 
significant 
fibrosis 
AUROC 
Limit 
KPa 
Se/Sp 
Gomez-
Dominguez et al. 
Mixt 94 82 0.74 4.0 94/33 
Fraqelli et al Mixt 200 50 0.86 7.6 81/76 
Chang et al Mixt 120 44 0.86 9.0 83/85 
Castera et al HCV 183 74 0.83 7.1 67/89 
Ziol et al HCV 251 65 0.79 8.8 56/91 
Yoneda et al NAFLD 67 49 0.87 6.6 83/81 
Abbreviations: HCV, hepatitis virus C, Se, sensitivity, Sp,specificity, NAFLD – non alcoholic fatty liver 
disease 
Table. 5. Fibroscan performance in detecting significant fibrosis (Guha & Rosenberg,2008) 
When comparing with liver biopsy, TE is non-invasive, easy to repeat, reproducible, 
without contraindications, highly performant technique for detecting cirrhosis. Its 
disadvantage is that unlike liver biopsy, TE is unable to discriminate between intermediate 
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stages of fibrosis. Comparing with serum markers, TE has lower applicability: failure in 5% 
of cases and unreliable results in 15% of cases.( Casterra, 2010). The known limits of this 
method are: the impossibility to conduct measurements in case of ascites (elastic waves do 
not propagate in liquids) and in patients with narrow intercostals spaces (it is necessary to 
insert the probe in the intercostals space). Another significant limiting factor is obesity (body 
mass index >28Kg/m2) due to the diminishing of the surface fat tissue signal. False positive 
results appear in case of acute hepatitis, extra hepatic cholestasis and congestive heart 
failure (Casterra, 2010). The combination between TE and serum markers increases 
diagnostic accuracy for liver fibrosis.  
3.2.2 Magnetic Resonance Elastography 
Magnetic resonance elastography (MRE) has the same basic principles as sonographic 
elastography. By using a probe (pneumatic or electromagnetic), placed directly on the 
patient’s abdominal wall, a shear wave is created. A specialized system of magnetic 
resonance measures the sequential propagation of the shear wave and transforms the data 
analyzed as an elastogram (color – encoded images). The analysis contains the liver in its 
entirety and allows assessing of fibrosis distribution, which is usually heterogeneous. 
Although until now the number of publications related to this method has been reduced, the 
results look promising. A study  which compared MRE with the APRI index in patients with 
viral or alcoholic liver diseases has  shown that MRE is more sensitive in detecting moderate 
and severe fibrosis than the APRI index. Among 96 patients with liver biopsy and 
noninvasive examinations  the reproducibility of both TE and MRE were excellent. The 
elasticity imaging techniques had greater diagnostic accuracy than APRI for detecting liver 
fibrosis. MRE was also found to be more accurate than TE for significant fibrosis (F≥2) and 
for cirrhosis diagnosis (Huwart 2008). 
The problems related to this technique refer to the increased exposure time (the exam takes 
60 minutes), the significant capital invested in the equipment and the computerized analysis 
system, the standardized measurement threshold and method reproducibility. In contrast 
with TE, MRE can be successfully performed in obese patients (BMI > 40 kg/m2 ). 
Furthermore, MRE had in part higher diagnostic accuracy in detecting significant fibrosis 
(F≥2) as compared with TE by examining of larger liver parenchyma areas (Huwart, 2008). 
Although modern magnetic resonance technique is not the most pragmatic noninvasive 
methods it is a promising method as regards the diagnosis potential of liver fibrosis. The 
acknowledgment of its diagnosis sensitivity still requires large population studies. 
3.2.4 Acoustic Radiation Force Imaging (ARFI) 
A new technique used to determine liver elasticity is ARFI elastography. The elastographic 
analysis model combines two technologies, ‘Virtual Touch tissue imaging™’ and ‘Virtual 
Touch tissue quantification™’, which allow the quantitative and qualitative analysis of liver 
elasticity. Using the Virtual Touch application, the tissue gets compressed via acoustic 
energy. It enables the physician to evaluate the mechanical characteristics of deep tissue and 
tissue changes. ARFI imaging (Virtual Touch tissue quantification ) measures liver stiffness 
within a defined region of interest (central window of 5mm axial by 4mm width), while 
performing real-time B-mode imaging. Transmission of short-duration (~262 sec) 
longitudinal acoustic pulses  with a fixed transmit frequency of 2.67 MHz leads micron-scale 
displacements in liver tissue, which results in a shear –wave propagation, away from the 
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region of excitation. Maximum movement is estimated by ultrasound detection fascicles 
adjacent to the central acoustic pulse. By measuring the maximum movement amplitude as 
compared to the time of each side fascicle, the shear – wave speed of the tissue can be 
reconstructed. Results expressed in meters per second are displayed by the machine 
(Friedrich-Rust, 2009).  
Preliminary results indicate that ARFI imaging technology is a promising method for the 
diagnosis of significant fibrosis in patients with chronic hepatitis C.( Friedrich-Rust, 2009, 
Fierbinteanu-Braticevici, 2009). The benefits of ARFI imaging as compared with Fibro scan 
consist in: lesser time consuming (new software allowed to the 12 measurements per 1min) 
and successful measurements in difficult patients (obese) because of subcostal scanning. 
Another advantage of ARFI imaging is that it is integrated into a conventional 
ultrasonography (US) system and can thus be performed during standard US examinations 
of the liver, which are routinely performed in patients with chronic liver disease. Further 
studies on large number of patients are needed in order to specify the role of ARFI 
elastography for noninvasive staging of liver fibrosis. 
3.3 Breath tests 
Taking into account that the liver has a complex and high metabolic capacity, translated into 
detoxification, synthesis, metabolization, storage, a unique  classical test  may not reflects all 
these sides. More, each function may be different affected in  various stages of the liver 
disease,  so that the determination of the reserve capacity of the liver appears to reflect a 
global functional image. During the last decade, several dynamic tests have been proposed 
to improve the functional diagnosis of liver diseases. Although numerous tests which 
explore a specific hepatic function have been used, these methods were not introduced in 
the clinical practice. 
The introduction of breath tests that use marked carbon (C13 ) attached to various substrata 
(aminopyrin, phenylalanin, methacetine, phenacetyne, galactose) was due to the need to 
have a quick and practical test to determine the functional hepatic reserve. While neither of 
these tests allows quantification of a global liver function, each has been shown to reflect the 
most important partial liver functions i.e. cytosolic, microsomal or mitochondrial function. 
The principle of breath tests is simple. An ingested substrate attached to C13 or C14, 
administered orally or parenterally is converted by the liver in 13 CO2 or 14CO2. The marked 
CO2 is collected at different time intervals in an alkaline environment which serves as a trap. 
The hepatic metabolism of the bonding substrate may be determined from a semi 
quantitative perspective by multiplying the specific CO2 activity in the exhaled air  within a 
given time interval. An ideal compound for this purpose is metabolized solely by the liver 
and therefore reflects liver function. 
In the beginning, breath tests required sophisticated and expensive mass spectrometers that 
were no longer used. 13C can now be measured with non dispersive infrared spectrometry, a 
simple and cost-saving method which provides information correlated with those of the 
mass spectrometry. Functional hepatic tests, including breath tests, together with clinic 
scores, had been proved to be helpful in diagnosis and prognosis of the patients with 
advanced hepatic disease. As regard the role of methacetin breath test  (MBT) in the 
assessement of fibrosis in patients with chronic hepatitic C, our study indicated that the 
methacetin breath test parameters didn’t allow differentiation of patients without fibrosis 
from those with mild fibrosis (F1). This limit was overcome by the fact that MBT was highly 
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correlated with significant fibrosis (≥ F2) which is considered the hallmark of progressive 
liver disease and a stronger indication for treatment.  
Additional studies are required to assess the role  of these tests as an alternative to liver 
biopsy in the diagnosis and follow-up of hepatic injury in patients with chronic liver 
diseases. 
4. Conclusion 
Liver biopsy remains an important tool in the evaluation and management of liver disease. 
However it  is invasive,  can cause significant complications and clearly, needle liver biopsy 
is far from an ideal test. Even though it is an imperfect “gold standard”, liver biopsy 
remains an important tool in the evaluation and management of liver disease. 
For this reason, the efforts to estimate the hepatic lesion stage through noninvasive methods 
are justified. Noninvasive investigations, such as various biomarkers, fibrosis scoring 
panels, imaging techniques and breath tests offer considerable promise in their ability to 
detect and to stage liver fibrosis. Until now, not even one noninvasive test can be considered 
enough sensitive to predict by itself the severity of acute or chronic liver diseases. That is 
why combining various noninvasive tests is promising and many times they can avoid liver 
biopsy. Further testing and validation are needed for these noninvasive procedures to refine 
their role of clinical practice and supplant the need for liver biopsy in chronic liver diseases. 
Now, when many non - invasive procedures have been studied, the question is if that do we 
still need a liver biopsy? We think that the answer is „yes”, because despite its limitations, 
the liver biopsy remains an invaluable procedure of the clinician, whenever  the etiology of 
liver disease is in impass. Liver biopsy is still needed if laboratory testing and imaging 
studies are inconclusive. It may take many years, if at all, until liver biopsy will be fully 
replaced. 
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